OBJECT: The characteristics of polyethylene glycol-coated liposomal doxorubicin (PLD), the only liposomal drug now clinically available for intravenous injection, were investigated after convection-enhanced delivery (CED) into the rat brain parenchyma. METHODS: The distribution, tissue retention, and toxicity profile were evaluated after CED into the rat brain parenchyma. The antitumor efficacy was also determined in rodent intracranial U-251MG and U-87MG glioma models. RESULTS: Convection-enhanced delivery of PLD achieved wider distributions and delayed onset of toxicity in the brain parenchyma compared with CED of free doxorubicin infusion. Fluorescence generated from doxorubicin infused as PLD was detected until at least 30 days after infusion. Local toxicity was not observed when a 10% dilution of the commercially available PLD solution was used (0.2 mg/ml doxorubicin), but was significant at higher concentrations. Results after 10% PLD was delivered locally with CED demonstrated significant survival prolongation in both intracranial U-251MG and U-87MG xenograft models. CONCLUSIONS: Convection-enhanced delivery of PLD achieved extensive tissue distribution and sustained drug release. Convection-enhanced delivery of PLD is a promising chemotherapy for the treatment of malignant gliomas.
OBJECT: The characteristics of polyethylene glycol-coated liposomal doxorubicin (PLD), the only liposomal drug now clinically available for intravenous injection, were investigated after convection-enhanced delivery (CED) into the rat brain parenchyma. METHODS: The distribution, tissue retention, and toxicity profile were evaluated after CED into the rat brain parenchyma. The antitumor efficacy was also determined in rodent intracranial U-251MG and U-87MG glioma models. RESULTS: Convection-enhanced delivery of PLD achieved wider distributions and delayed onset of toxicity in the brain parenchyma compared with CED of free doxorubicin infusion. Fluorescence generated from doxorubicin infused as PLD was detected until at least 30 days after infusion. Local toxicity was not observed when a 10% dilution of the commercially available PLD solution was used (0.2 mg/ml doxorubicin), but was significant at higher concentrations. Results after 10% PLD was delivered locally with CED demonstrated significant survival prolongation in both intracranial U-251MG and U-87MG xenograft models. CONCLUSIONS: Convection-enhanced delivery of PLD achieved extensive tissue distribution and sustained drug release. Convection-enhanced delivery of PLD is a promising chemotherapy for the treatment of malignant gliomas.
Authors: Neal Luther; Nai-Kong Cheung; Eleni P Souliopoulos; Ioannis Karampelas; Ioannis Karempelas; Daniel Bassiri; Mark A Edgar; Hong-Fen Guo; Ira Pastan; Philip H Gutin; Mark M Souweidane Journal: Mol Cancer Ther Date: 2010-04-06 Impact factor: 6.261
Authors: William T Phillips; Beth Goins; Ande Bao; Daniel Vargas; Juan E Guttierez; Abram Trevino; Jessica R Miller; James Henry; Richard Zuniga; Giacomo Vecil; Andrew J Brenner Journal: Neuro Oncol Date: 2012-03-16 Impact factor: 12.300
Authors: Michael J Cima; Heejin Lee; Karen Daniel; Laura M Tanenbaum; Aikaterini Mantzavinou; Kevin C Spencer; Qunya Ong; Jay C Sy; John Santini; Carl M Schoellhammer; Daniel Blankschtein; Robert S Langer Journal: J Control Release Date: 2014-05-04 Impact factor: 9.776
Authors: Nikhil Dube; Jessica Y Shu; He Dong; Jai W Seo; Elizabeth Ingham; Azadeh Kheirolomoom; Pin-Yuan Chen; John Forsayeth; Krystof Bankiewicz; Katherine W Ferrara; Ting Xu Journal: Biomacromolecules Date: 2013-10-03 Impact factor: 6.988
Authors: Garrett W Astary; Svetlana Kantorovich; Paul R Carney; Thomas H Mareci; Malisa Sarntinoranont Journal: J Neurosci Methods Date: 2010-01-11 Impact factor: 2.390